Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.8K
Cancer Therapies02:49

Cancer Therapies

7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

5.0K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.0K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Cancer Vaccines01:30

Cancer Vaccines

492
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
492
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Vitiligo Information Resource database v3.

NPJ systems biology and applications·2026
Same author

Corrigendum to <'Co-localization and co-expression of Olfml3 with Iba1 in brain of mice'> <[Journal of Neuroimmunology, 394 (2024) 1-12/578411]>.

Journal of neuroimmunology·2026
Same author

Protein Kinase C-Delta (PKCδ) inhibition stabilizes endothelium and suppresses triple-negative breast cancer (TNBC) intravasation in a microfluidic hypoxic tumor model.

Bioengineering & translational medicine·2026
Same author

Investigating the Anticancer Promise of Synthesized Methylated N-Substituted-4-Hydroxy-2-Quinolone-3-Carboxamides: Biological and Computational Characterization.

Chemical biology & drug design·2026
Same author

Vacuolization as a Novel Approach to Cancer Therapy.

Journal of biochemical and molecular toxicology·2026
Same author

Breath by Breath: Navigating the Landscape of Exhaled Breath in Clinical Research and Prospects for the Future.

Journal of analytical methods in chemistry·2026
Same journal

Patterns of Body Composition Changes and Their Predictors During Cancer Therapy in Newly Diagnosed Adult Oncology Patients With Varying Baseline Nutritional Status at a Tertiary Hospital in Ethiopia: A Prospective Cohort Study.

Cancer reports (Hoboken, N.J.)·2026
Same journal

Advancing Cancer Cachexia Drug Development: Leveraging Biomarkers and Functional Endpoints to Optimize Trial Design.

Cancer reports (Hoboken, N.J.)·2026
Same journal

Salvage Therapy With Inotuzumab Ozogamicin in Relapsed/Refractory B-ALL After CAR-T Therapy and HSCT: A Case Series.

Cancer reports (Hoboken, N.J.)·2026
Same journal

Development of a Tumor-Bearing Animal Model to Evaluate Chemotherapy Efficacy and Toxicity.

Cancer reports (Hoboken, N.J.)·2026
Same journal

CCT7 Expression Affects the Prognosis of Lung Adenocarcinoma.

Cancer reports (Hoboken, N.J.)·2026
Same journal

Pembrolizumab-Induced Myositis: Diagnostic and Therapeutic Challenges From Two Case Reports and a Narrative Review.

Cancer reports (Hoboken, N.J.)·2026
See all related articles

Related Experiment Video

Updated: Aug 26, 2025

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
09:12

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

371

Oncology biosimilars: New developments and future directions.

Rinda Devi Bachu1, Mariam Abou-Dahech1, Swapnaa Balaji1

  • 1Department of Pharmacology and Experimental Therapeutics, College of Pharmacy & Pharmaceutical Sciences, University of Toledo, Toledo, Ohio, USA.

Cancer Reports (Hoboken, N.J.)
|October 4, 2022
PubMed
Summary
This summary is machine-generated.

Biosimilars offer a promising solution to reduce cancer treatment costs by providing more accessible alternatives to expensive biologics. Understanding their development, regulation, and safety is crucial for widespread adoption and patient benefit.

Keywords:
bevacizumabbiosimilarsepoetinsfilgrastimnew developmentsoncologypegfilgrastimrituximab

More Related Videos

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.1K

Related Experiment Videos

Last Updated: Aug 26, 2025

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research
09:12

High-Throughput Automated Multiplex Immunofluorescence Assays for Translational Research

Published on: June 10, 2025

371
Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer
07:59

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

1.2K
Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer
08:26

Author Spotlight: Advancing Personalized Medicine in Ovarian Cancer

Published on: February 23, 2024

2.1K

Area of Science:

  • Oncology
  • Pharmacology
  • Biotechnology

Background:

  • Biologics are essential in cancer therapy but are costly, limiting patient access.
  • High development and manufacturing expenses of biologics burden healthcare systems.
  • Patent expirations for biologics pave the way for cost-saving biosimilars.

Purpose of the Study:

  • To review legislation, regulations, pharmacoeconomics, and stakeholder perceptions of biosimilars.
  • To provide an overview of currently available and developing biosimilars in oncology.
  • To address challenges and uncertainties surrounding biosimilar adoption.

Main Methods:

  • Literature review of regulatory guidelines and scientific society recommendations.
  • Analysis of pharmacoeconomic data related to biologics and biosimilars.
  • Examination of market data for available and developing biosimilars.

Main Results:

  • Established and evolving regulatory frameworks facilitate biosimilar development.
  • Biosimilars present potential cost reductions, enhancing treatment accessibility.
  • Knowledge gaps and immunogenicity concerns remain barriers to biosimilar acceptance.

Conclusions:

  • Biosimilars are critical for improving access to advanced cancer therapies.
  • Continued regulatory refinement and education are needed to overcome adoption hurdles.
  • Further research on immunogenicity and long-term safety is essential.